Navigation Links
Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification

ion label for Flurizan."

About Flurizan(TM)

Myriad has two Phase 3 trials of Flurizan ongoing in patients with mild Alzheimer's disease. In each study, participants are taking 800 mg of Flurizan or placebo twice daily, and participants enrolled will have taken the study drug for 18 months. Flurizan is the first in a new class of drug candidates known as Selective Amyloid beta-42 Lowering Agents (SALAs). Flurizan lowered levels of Abeta42 in cellular assays and animal models. Abeta42 is the primary constituent of senile plaque that accumulates in the brain of patients with Alzheimer's disease. It is thought to be the key initiator of Alzheimer's disease, since Abeta42 has the greatest tendency to aggregate, cause neuronal damage and initiate amyloid deposits in the brain. Most genetic mutations that cause early-onset Alzheimer's disease appear to do so by increasing production of Abeta42. Myriad believes that Flurizan is the most advanced drug candidate that modifies the production of Abeta42 to be evaluated in a clinical trial for the treatment of Alzheimer's disease.

About Myriad

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development and marketing of novel healthcare products. The Company develops and markets molecular diagnostic products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com. Flurizan is a trademark of Myriad Genetics, Inc. in the United States and other countries.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include whether the Flurizan Phase 3 study design may demonstrate disease modification; the Company's use of the Natural History Staggered Start trial design and trial analysis methodology in its Flurizan Phase
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Myriad Genetics Presents Tumor Origin Technology at AACR
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:3/27/2015)... 27, 2015 Levi & Korsinsky announces it ... OHRP ) concerning possible violations of federal securities ... Company in connection with its study of the drug ... or contact Joseph E. Levi, Esq. ... telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
(Date:3/27/2015)... /PRNewswire/ - Medicure Inc. (the "Company") (TSXV:MPH, OTCQB:MCUJF) announces ... grant of an aggregate of 236,070 options to certain ... the Company pursuant to the Company,s Stock Option Plan. ... the tenth anniversary of the date of grant, 5,000 ... the date of grant and 50,000 are set to ...
(Date:3/27/2015)... /CNW Telbec/ - Russell Williams , President of ... welcomes the 2015-2016 Quebec Budget, noting the fiscal discipline ... biopharmaceutical industry. However, the association is concerned about the ... the government,s intent to strive for a balanced budget ... Quebec,s economic development is encouraging," ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
... DHAKA, Bangladesh, Feb. 7, 2011 ... million people served by just 11 modern radiotherapy linear ... Varian Medical Systems (NYSE: VAR). Treatments using fast and ... a new Clinac® iX medical linear accelerator at the ...
... 7, 2011 Amarin Corporation plc (Nasdaq: AMRN ... the Leerink Swann Hot Topics in Therapeutics Roundtable Conference on ... discussion on Cardiology at 7:45am ET and a company presentation ... Roosevelt Hotel in New York City. A live ...
Cached Medicine Technology:Cancer Patients in Bangladesh Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems 2Cancer Patients in Bangladesh Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems 3Amarin to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference 2
(Date:3/27/2015)... 2015 Bleeding is one of ... coronary intervention (PCI), resulting in increased mortality, morbidity, ... paradox,” in which the highest-risk PCI patients with ... less often with bleeding avoidance strategies than lower-risk ... America Heart Institute asked the question whether prospectively ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 Healthpointe ... Stanley G. Katz, M.D., is now treating knee and ... including Anaheim , Long Beach, and La Mirada. ... of acute knee and hip joint disorders as well ... Katz is passionate in returning his patients back to ...
(Date:3/27/2015)... Ticket Down is a reputable source for authentic tickets ... a phenomenal and highly successful live tour last year, the cast ... tour again in 2015 and they will be visiting 8 cities ... in New York City at the cozy Beacon Theatre and will ... 10th. , Fans of the hit show can look forward to ...
(Date:3/27/2015)... While deep learning was the topic of many ... , the CEO of one start-up spoke passionately about using ... well beyond the generally-agreed ceiling of 120 years. , Insilico ... of 12 companies recognized as the hottest GPU-powered startups in ... GTC Emerging Companies Summit have business models focused on ...
(Date:3/27/2015)... 2015 According to a recently published ... plate and screw market in Europe is in decline ... and screw segment. Price decreases are being seen across ... 50% of the total European trauma device market, continued ... market value, year after year. , “Such price ...
Breaking Medicine News(10 mins):Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3
... The Center for ... with the flu (influenza). On average, the influenza virus leads to 20,000 to 40,000 American ... deaths by offering free flu shots . , ... Plano, TX (Vocus) September 12, 2009 -- Starting Monday, September 14th, the Plano location ...
... Hernandez, Ph.D., M.P.H.an assistant professor at the University of ... that body mass in younger and older adulthood, and ... man,s risk for prostate cancer. This risk varies among ... study published in Cancer Epidemiology, Biomarkers & Prevention ...
... , TAMPA, Fla. and SAN FRANCISCO, Sept. ... agreement to roll out Demandforce D3, a web-based patient communications ... in Florida and Georgia. Coast Dental, the leading dental provider ... pilot. , , Coast Dental integrated the ...
... NEW YORK, Sept. 11 Duane Reade Holdings Inc., ... as the Local Presenting Sponsor of the 2009 Komen New York ... foundation, The Duane Reade Charitable Foundation, have raised $330,000 to increase ... find a cure. This marks the third year that Duane Reade ...
... , LIONVILLE, Pa., Sept. 11 ... that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer, ... 7th Annual Best Ideas Conference 2009, being held September 16-17, 2009 ... the UBS Global Life Sciences Conference, being held September 21-23, 2009 ...
... ROCHESTER, Minn., Sept. 11 Mayo Clinic researchers ... may help them diagnose cardiac infections without an invasive exam. ... on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. , ... ) , , Endocarditis -- an infection ...
Cached Medicine News:Health News:H1N1 frenzy may allow regular flu to be more deadly than ever 2Health News:University of Hawaii at Manoa CRCH scientists report adulthood body size associated with cancer risk 2Health News:Coast Dental Deploys Demandforce D3 Communications Platform 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3Health News:West to Present at Two Upcoming Investor Conferences 2Health News:Artificial Intelligence Helps Diagnose Cardiac Infections 2Health News:Artificial Intelligence Helps Diagnose Cardiac Infections 3
Constructed from soft Shur-grip foam and velcro closure for easy application and - reapplication...
... Cobalt Binding (ACB®) Test is a clinical ... (IMA®) by measuring the cobalt binding capacity ... First identified in the early 1990s, IMA ... contact with ischemic tissue in the heart. ...
... Albumin Cobalt Binding (ACB®) Test is a ... Albumin (IMA®) by measuring the cobalt binding ... sample. First identified in the early 1990s, ... in contact with ischemic tissue in the ...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
Medicine Products: